The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients.

Slides:

Advertisements

Similar presentations

Comparison of the Constipation Assessment Scale and Plain Abdominal Radiography in the Assessment of Constipation in Advanced Cancer Patients Kittiphon.

Advertisements

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain Xiaowei.

Palliative Sedation at Home for Terminally Ill Children With Cancer

Morphine Inhalation by Cancer Patients: A Comparison of Different Nebulization Techniques Using Pharmacokinetic, Spirometric, and Gasometric Parameters

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Effect of Tubing on Loss of Clonazepam Administered by Continuous Subcutaneous Infusion Jennifer J. Schneider, BPharm(Hons), PhD, Phillip Good, MBBS,

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

Steady-State Kinetics and Dynamics of Morphine in Cancer Patients

A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain Richard L. Rauck, MD, Mark S. Wallace,

A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations Mary E. Lynch,

A Randomized Trial of the Effectiveness of Topical “ABH Gel” (Ativan®, Benadryl®, Haldol®) vs. Placebo in Cancer Patients With Nausea Devon S. Fletcher,

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium in Patients with Advanced Cancer: A Preliminary Study Ahmed Elsayem, MD, Shirley H. Bush, MBBS,

Pain Severity in Diabetic Peripheral Neuropathy is Associated with Patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep Mugdha Gore,

Hospice and Palliative Care Development in Africa: A Multi-Method Review of Services and Experiences David Clark, PhD, Michael Wright, PhD, Jennifer.

What Palliative Care-Related Problems Do Patients Experience at HIV Diagnosis? A Systematic Review of the Evidence Victoria M. Simms, MSc, Irene J. Higginson,

The adequacy of the minimum data set assessment of pain in cognitively impaired nursing home residents Jiska Cohen-Mansfield, PhD, ABPP Journal of Pain.

Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable

What Influences Patients’ Decisions on Artificial Hydration at the End of Life? A Q- Methodology Study Catherine Malia, MSc, Michael I. Bennett, MB, ChB,

Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced Cancer Alfredo H. Navigante, MD, PhD,

Gregory P. Samsa, PhD, Steven Wolf, MB, Thomas W

Opioid Metabolites Journal of Pain and Symptom Management

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

Bettina N. Nielsen, MSc, Gitte Aagaard, RN, Steen W

Pre-Emptive Value of Methylprednisolone Intravenous Infusion in Patients With Vertebral Metastases. A Double-Blind Randomized Study Ayman Abd Al-maksoud.

Clearance of Meperidine and Its Metabolite Normeperidine in Hemodialysis Patients With Chronic Noncancer Pain Che-Hao Hsu, MD, Tso-Chou Lin, MD, Chih-Cherng.

Eduardo Bruera, MD, Raul Sala, MD, Odette Spruyt, MD, J

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain Xiaowei.

The Direct and Indirect Costs of Opioid-Induced Constipation

Bruce H. Chamberlain, MD, Karen Cross, MD, Jaron L

Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study Neil A. Hagen, MD, FRCPC, Patrick du Souich,

What Can We Learn About the Spiritual Needs of Palliative Care Patients From the Research Literature? Mark Cobb, MA, Christopher Dowrick, MD, FRCGP,

David Clark, PhD, Michael Wright, PhD

Redefining Appropriate Treatment Expectations

Amy Z. Boelk, PhD, MSSW, Betty J. Kramer, PhD, MSSW

Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and.

A Randomized Trial of the Effectiveness of Topical “ABH Gel” (Ativan®, Benadryl®, Haldol®) vs. Placebo in Cancer Patients With Nausea Devon S. Fletcher,

Palliative Sedation at Home for Terminally Ill Children With Cancer

Subcutaneous Lymphatic Drainage (Lymphcentesis) for Palliation of Severe Refractory Lymphedema in Cancer Patients Juliet Jacobsen, MD, DPH, Craig D.

Use of the Palliative Performance Scale (PPS) for End-of-Life Prognostication in a Palliative Medicine Consultation Service Francis Lau, PhD, Vincent.

Jodi L. Hannan, MD, Steven M. Radwany, MD, Terry Albanese, PhD

Multicentre evaluation of the adenosine agonist GR79236X in patients with dental pain after third molar extraction J.R. Sneyd, J.A. Langton, L.G. Allan,

Evaluation of Methadone Absorption After Topical Administration to Hospice Patients Robert K. Sylvester, PharmD, Caroline Schauer, RN, John Thomas, MD,

Characteristics Associated With Physical Function Trajectories in Older Adults With Cancer During Chemotherapy Melisa L. Wong, MD, MAS, Steven M. Paul,

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

Robert L. Jayes, MD, Robert M. Arnold, MD, Erik K. Fromme, MD

Do Interference-Based Cut-Points Differentiate Mild, Moderate, and Severe Levels of 16 Cancer-Related Symptoms Over Time? Sangchoon Jeon, MS, Charles.

Pharmacokinetics of Phenobarbital in Microenema Via Macy Catheter Versus Suppository Y.W. Francis Lam, PharmD, FCCP, Ansom Lam, MD, Brad Macy, RN, BSN,

Antonio T. Fernando, MD, Nathan S. Consedine, PhD

Efficacy of intravenous magnesium in neuropathic pain

U.S. Hospice Benefits Journal of Pain and Symptom Management

Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness—An Exploratory Study Diana H. Ferreira,

The Spiritual Needs Assessment for Patients (SNAP): Development and Validation of a Comprehensive Instrument to Assess Unmet Spiritual Needs Rashmi K.

Is the B12/CRP Index More Accurate Than You at Predicting Life Expectancy in Advanced Cancer Patients? Filipa Tavares, MD Journal of Pain and Symptom.

Development and Reliability Testing of the Victoria Bowel Performance Scale (BPS) G. Michael Downing, MD, Craig Kuziemsky, PhD, Mary Lesperance, PhD,

Association Between Symptom Distress and Survival in Outpatients Seen in a Palliative Care Cancer Center J. Lynn Palmer, PhD, Michael J. Fisch, MD, MPH

Karen E. Steinhauser, PhD, Corrine I. Voils, PhD, Hayden B

Margot E. Kurtz, PhD, Jay C. Kurtz, PhD, Charles W

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate- Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two.

Providing Constant Analgesia with OROS® Hydromorphone

Morphine Bioavailability from a Topical Gel Formulation in Volunteers

Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel.

Steady-State Pharmacokinetic Comparison of a New, Extended-Release, Once-Daily Morphine Formulation, Avinza™, and a Twice-Daily Controlled-Release Morphine.

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency Richard L. Wasserman, MD, PhD,

Helping Patients with Advanced Cancer Live with Concerns About Eating: A Challenge for Palliative Care Professionals Jane Hopkinson, PhD, RGN, Jessica.

The bioavailability of morphine applied topically to cutaneous ulcers

How Should End-of-Life Advance Care Planning Discussions Be Implemented According to Patients and Informal Carers? A Qualitative Review of Reviews Alex.

Associations Between Physical Activity and Quality of Life in Cancer Patients Receiving Palliative Care: A Pilot Survey Sonya S. Lowe, MD, MSc, Sharon.

Use of Pregabalin in the Management of Chronic Uremic Pruritus

Presentation transcript:

The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients with Advanced Illness Jay R. Thomas, MD, PhD, Mark S. Wallace, MD, Richard C. Yocum, MD, Daniel E. Vaughn, PhD, Michael F. Haller, PhD, Jocelyne Flament, MD Journal of Pain and Symptom Management Volume 38, Issue 5, Pages 663-672 (November 2009) DOI: 10.1016/j.jpainsymman.2009.03.009 Copyright © 2009 Terms and Conditions

Fig. 1 Randomized sequence of injections. A, intravenous morphine; B, subcutaneous morphine with placebo; C, subcutaneous morphine with rHuPH20. Journal of Pain and Symptom Management 2009 38, 663-672DOI: (10.1016/j.jpainsymman.2009.03.009) Copyright © 2009 Terms and Conditions

Fig. 2 Tmax (mean ± SD) and Cmax (geometric mean ± DS) of morphine for each administration method. Journal of Pain and Symptom Management 2009 38, 663-672DOI: (10.1016/j.jpainsymman.2009.03.009) Copyright © 2009 Terms and Conditions

Fig. 3 Pharmacokinetic curves for morphine plasma concentration over four hours postinjection (population means ± SDs) for each administration method. Journal of Pain and Symptom Management 2009 38, 663-672DOI: (10.1016/j.jpainsymman.2009.03.009) Copyright © 2009 Terms and Conditions

Fig. 4 Pharmacokinetic curves for morphine plasma concentration over the first 30minutes postinjection (population means ± SDs) for each administration method. Journal of Pain and Symptom Management 2009 38, 663-672DOI: (10.1016/j.jpainsymman.2009.03.009) Copyright © 2009 Terms and Conditions

Fig. 5 Morphine AUC0−t (geometric mean +/− DS) for each administration method. Journal of Pain and Symptom Management 2009 38, 663-672DOI: (10.1016/j.jpainsymman.2009.03.009) Copyright © 2009 Terms and Conditions

Fig. 6 Scores for severity of a) injection-site edema, (0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe) b) rash (0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe), and c) discomfort (0 = no discomfort, 100 = worst possible discomfort [100 mm VAS scale]). Journal of Pain and Symptom Management 2009 38, 663-672DOI: (10.1016/j.jpainsymman.2009.03.009) Copyright © 2009 Terms and Conditions